[Treatment of giant cell tumor of distal radius with vascular anastomosis with proximal graft of vascular].

Objective: To evaluate the curative effect of proximal fibula graft of vascular anastomosis for giant cell tumor(GCT) of distal radius of bone. Methods: 38 patients with distal radius GCT were treated with proximal articular graft of anastomotic vessels. We evaluated the wrist joint function before and after surgery using wrist activity, visual analogue scale(VAS)pain score, grip recovery rate and Cooney scoring system. Results: All patients' wounds healed in stage I, and recovered smoothly during the perioperative period. No obvious wrist deformity was observed during the follow-up period. Bony union was achieved at the tibial and humerus osteotomy ends. The average healing time was 11 weeks. At third month postoperatively, the patient's wrist motion ranged from dorsiflexion to palmar flexion (69.15±15.24)°, ulnar/spasm deviation was (22.74±10.55)°, grip strength was (88.69±12.75)%, wrist VAS pain The score was (2.45±1.11) points and the Cooney score was (89.58±11.25) points, which was significantly better than preoperation (all P<0.05). No recurrence or metastasis occurred during follow-up in all patients. Conclusions: Distal humerus GCT treated with distal radius with vascular anastomosis with proximal graft of vascular has little effect on the activity of the lower extremities. However, its reconstruction of the wrist joint function might achieve better results.

Giant cell tumor of the sacrum treated with selective arterial embolization.

Giant cell tumor of the sacrum is extremely difficult to manage. Standard treatments, including surgery and radiation, are associated with significant complications and recurrence rates. In this manuscript, we report an early clinical result of a case of giant cell tumor of the sacrum successfully managed with selective arterial embolization. A 56-year-old woman underwent selective embolization for management of giant cell tumor of the sacrum. Radiologically, massive shrinkage of the extraosseous mass and increased peripheral ossification were obvious. Clinically, rapid pain relief was achieved and gait disability recovered. At final follow-up 28 months after completion of treatment, she retained normal activity in daily life. We stress the effectiveness of selective arterial embolization as a less invasive and less complicated primary treatment of giant cell tumors of the sacrum.

Preoperative embolisation in benign bone tumour excision.

PURPOSE: To assess the role of preoperative embolisation in benign bone tumour excision. METHODS: 3 men and 3 women aged 19 to 35 (mean 23) years with either a giant cell tumour or an aneurysmal bone cyst in limb girdle sites underwent preoperative embolisation a day prior to wide local excision by the same surgeon. Tumour size, blood loss, wound healing, infection, and tumour recurrence were assessed. RESULTS: The mean total blood loss was 391 (range, 100-980) ml. No blood transfusion was needed. No patient had any surgery- or embolisation-associated complication. No tumour recurred within a minimum 5-year follow-up. All patients had satisfactory limb function. CONCLUSION: Preoperative embolisation is useful in the management of vascular and aggressive bone tumours located at limb girdle sites where a tourniquet cannot be used.

Postembolization paralysis in a man with a thoracolumbar giant cell tumor.

Giant cell tumors are hypervascular tumors that represent approximately 5% of all primary bone neoplasms. Vertebral tumors often require surgery to maintain spinal stability or to relieve spinal cord and nerve root compression. However, surgical resection of hypervascular tumors like giant cell tumors can be hazardous because of the risk of excessive intraoperative hemorrhage. Preoperative embolization can be useful to decrease perioperative blood loss in primary and metastatic vertebral tumors, and preoperative embolization for vertebral tumor surgery is relatively safe. We report a patient who had the unusual but serious complications of paralysis and paresthesia at the T12 vertebra and below as a result of preoperative embolization. At 6 months followup, the patient was disease-free but without neurologic function from T12 and below. Therefore, it is imperative physicians be aware of the possible preoperative embolization complication of cord infarction and the safety measures proposed in this article to avoid this complication.

Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws.

PURPOSE: Giant cell tumors are classified and treated based on their biologic behavior. We hypothesize that they are proliferative vascular lesions and would be expected to respond to antiangiogenic therapy. The purpose of this report is to present a treatment protocol consisting of enucleation, with preservation of vital structures, followed by subcutaneous interferon alpha. MATERIALS AND METHODS: Patients with a biopsy-confirmed giant cell lesion satisfying criteria for "aggressive giant cell tumor" were included. Instead of wide en bloc resection, lesions were enucleated and the patients started on interferon alpha-2 or beta (3,000,000 units/m(2)) 48 to 72 hours postoperatively. The subjects were followed by clinical examination and radiography, immediately after surgery and every 3 months until the bone cavity completely healed. Thereafter, follow-up was every 6 months. RESULTS: Eight patients (7 females), with a mean age of 18.7 +/- 11.1 years, have been enrolled. Six tumors were in the posterior mandible, and 2 were in the anterior maxilla. The mean size was 29.0 mm (range, 15 to 70 mm). All patients underwent enucleation. There were no postoperative complications, and all patients tolerated interferon. There was no evidence of tumor growth during treatment. Seven of 8 patients have completed interferon therapy, and there have been no recurrences during 1 to 6 years of follow-up. The other patient continues on treatment with no evidence of disease. CONCLUSION: Antiangiogenic therapy, in combination with curettage, is a promising strategy for treatment of aggressive giant cell tumors. Combined treatment results in a high rate of tumor control with decreased operative morbidity compared with conventional treatment.

Abrupt and complete occlusion of tumor-feeding vessels by gamma-linolenic acid.

For legal reasons this article has been removed by the publisher

Biomedical technology revolution: opportunities and challenges for oral and maxillofacial surgeons.

During this 45-minute presentation, I have tried to describe my vision of the exciting future that awaits us. I have tried to impart my enthusiasm for the opportunities provided to us as surgeons by the advances in molecular biology and genetics, imaging, surgical technology and bioinformatics. Most of all, I hope I have transmitted my optimism for the future to our younger members. I think the following statement or observation by the great educator Margaret Mead accurately summarizes our current situation regarding the application of all this new knowledge that will become available to us as surgeons: 'We are now at the point where we must educate people (surgeons) in what nobody knew yesterday, and prepare in our schools (training programs) for what no one knows yet but what some people must know tomorrow.'

[Characteristic perfusion pattern of osseous giant cell tumor in dynamic contrast-enhanced MRI]. / Charakteristisches Perfusionsmuster des ossären Riesenzelltumors in der dynamischen kontrastverstärkten MRT.

PURPOSE: To describe the perfusion pattern of giant cell tumor (GCT) of bone with Gd-enhanced dynamic MR imaging. To compare time-intensity-curves in patients with local recurrence and postoperative alterations without recurrence. METHODS: Nine patients (5 women, 4 men) with GCT of bone underwent 19 dynamic MRI examinations. Mean age was 34 years (range 24-64 years). All diagnoses were proven by pathology. Dynamic contrast-enhanced MRI was performed at 1.0 T using T1-weighted gradient echo sequences. GCT was located in the distal radius (4x), tibia (3x), fibula (1x) and humeral head (1x). RESULTS: All giant cell tumors showed a uniform perfusion pattern with a steep slope and maximum intensity value followed by an early and rapid washout phase. The same pattern appeared in five local recurrences of GCT in four patients. In nine follow-up examinations without local recurrence dynamic MRI yielded in uncharacteristic perfusion patterns. CONCLUSION: These results demonstrate a uniform perfusion pattern of GCT of bone obtained by dynamic MRI. It is characterized by a steep slope followed by an early and rapid washout phase. This characteristic pattern can also be obtained in local recurrences. Dynamic contrast-enhanced MRI appears a helpful method for primary diagnosis of GCT of bone and detection of local recurrences after surgery.

Gene expression of vascular endothelial growth factor in giant cell tumors of bone.

The production of vascular endothelial growth factors (VEGF), a major cause of neoangiogenesis, is a prerequisite for tumor growth and invasion. VEGF have also been shown to be important for the formation of osteoclasts. Because giant cell tumors of bone (GCT) are frequently hypervascular and have the ability to recruit macrophages and multinucleated osteoclast-like giant cells, we evaluated the levels of VEGF gene transcript in several of these tumors using Northern blot analyses, semiquantitative reverse transcription polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), and immunohistochemistry. Our results showed that three major isoforms of VEGF (121, 165, and 189) were expressed in all cases of GCT investigated, with isoform 121 transcripts the most abundant. By both FISH and immunohistochemistry, we have shown that VEGF was present in spindle-shaped stromal-like tumor cells, round macrophage-like cells, and osteoclast-like multinucleate giant cells. Moreover, we have shown that the levels of VEGF gene expression but not microvessel density correlated with Enneking's clinical stage of GCT. There were higher levels of VEGF gene expression in stage III GCT than in stage I/II GCT (P < .0357). In conclusion, our results indicate that overexpression of VEGF may be associated with the advanced stage of the neoplasm.

Giant-cell tumour involving the cranial vault: imaging and treatment.

A giant-cell tumour involving the cranial vault was diagnosed in a 37-year-old man who presented with a large swelling at the vertex. The role of imaging in the diagnosis and treatment of this tumour is described. On CT and MRI the appearances were nonspecific and the diagnosis was established by histological examination after removal of the tumour. A preoperative angiogram showed a tumour blush and before surgery, embolisation was performed via the percutaneous and transarterial routes.

Immunohistochemical and ultrastructural evidence of a modified microvasculature in the giant cell granuloma of the jaws.

A panel of five immunohistochemical markers, MB1, leukocyte common antigen, S-100 protein, smooth muscle specific actin, and factor VIII related antigen, were used to study 20 giant cell lesions. These included eight central giant cell granulomas, nine peripheral giant cell granulomas, and three giant cell tumors of bone. The multinucleated giant cells stained positively with MB1, the mononuclear round cells were positive to leukocyte common antigen and the spindle cells were unreactive to all the markers chosen in all the lesions. The most interesting finding was the staining pattern of the blood vessels to factor VIII related antigen in the giant cell granuloma. The blood vessels on the periphery of the lesions were strongly positive for this antibody. However, reaction product was not evident deeper in the lesion within the aggregations of giant cells. Two other endothelial cell markers, Ulex europaeus 1 lectin and QBend 10 were used to study 10 giant cell lesions and a similar pattern of staining was observed. Transmission electron microscopy was subsequently used to study the ultrastructure of the microvasculature of three peripheral giant cell granulomas, and the findings indicated that the reasons for the differential staining may lie in the differences in the structure of the microcirculation.

Relationship between microvascular structure and biological characteristics of giant cell tumour of bone.

The vascular architecture of bone giant cell tumor was observed histologically with resin cast technique and scanning electron microscopy. Three types of capillaries were noted in the tumor tissue: extruding club-like capillary in the outer zone of the tumor; sinusoid capillary running disorderly in the intermediate zone; cecum capillary in the central zone. The pattern of vascular structure was believed to be correlated with tumor growth.